Edition:
United States

People: OPKO Health Inc (OPK.O)

OPK.O on Nasdaq

2.10USD
16 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.10
Open
$2.16
Day's High
$2.18
Day's Low
$2.10
Volume
2,806,320
Avg. Vol
4,624,779
52-wk High
$6.40
52-wk Low
$1.73

Frost, Phillip 

Dr. Phillip Frost serves as Chairman of the Board and Chief Executive Officer at Opko health, Inc. Dr. Frost has been the Chief Executive Officer of the Company and Chairman of the Board since March 2007. Dr. Frost serves as a director for Castle Brands (NYSE American:ROX), a developer and marketer of premium brand spirits, and Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a publicly traded biotechnology company developing new treatments for viral diseases. He serves as a member of the Board of Trustees of the University of Miami, the Skolkovo Foundation Scientific Advisory Council in Russia, the Shanghai Institute for Advanced Immunochemical Studies in China, and The Florida Council of 100 and as a Trustee of each of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He serves as Chairman of Temple Emanu-El, Governor of Tel Aviv University and is a member of the Executive Committee of The Phillip and Patricia Frost Museum of Science. Dr. Frost served as a director of Ladenburg Thalmann Financial Services Inc. (“Ladenburg Thalmann”) (NYSE American:LTS), an investment banking, asset management, and securities brokerage firm providing services through its principal operating subsidiary, Ladenburg Thalmann & Co. Inc., from 2004 to 2018 and had served as its Chairman from July 2006 until September 2018, a director of Teva Pharmaceutical Industries, Limited, or Teva (NYSE:TEVA) from January 2006 until February 2015 and had served as Chairman of the Board of Teva from March 2010 until December 2014. Dr. Frost previously served as Vice Chairman of Cogint, Inc., now known as Fluent, Inc. (NASDAQ:FLNT), and as a director for Sevion Therapeutics, Inc. prior to its merger with Eloxx Pharmaceuticals, Inc., and TransEnterix, Inc., (NYSE American:TRXC). Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation (“IVAX”) from 1987 until its acquisition by Teva in January 2006. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals, Inc.

Basic Compensation

Total Annual Compensation, USD 960,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,076,000
Fiscal Year Total, USD 2,036,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 1,987,500 11,250,400.00
Name Fiscal Year Total

Phillip Frost

2,036,000

Geoff Monk

--

Jane Hsiao

1,976,000

Adam Logal

1,250,000

Jon Cohen

--

Steven Rubin

1,460,000
As Of  30 Dec 2018